BridgeMD
Molecular imaging exploration of ocular angiogenic activity and evaluation of its value in therapeutic follow-up of AMD patients
EU CTIS ID: 2024-516970-31-00
What this study is testing
Evaluate the ability of 68Ga-NODAGA-RGD PET imaging to demonstrate, in 20 patients with unilateral AMD, a molecular therapeutic response to intraocular antiangiogenic injections at the end of the induction phase (after 3 months of treatment).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- signed informed consent
- Patient with unilateral AMD, with at least 1 focus of choroidal neovascularization on OCT, naïve to any antiangiogenic treatment.
- Initial check-up including at least OCT and visual acuity measurement, maximum 1 month old at the time of the 68Ga-NODAGA-RGD PET scan
- affiliation to a social security scheme.
You likely can't join if
- pregnant or breast-feeding women
- Age ≤ 18 years
- Patients with bilateral AMD
- Patients with AMD with no neovascularization focus as assessed by the standard diagnostic battery
- Patients previously treated with antiangiogenic therapy.
- Patients suffering from any other ophthalmological pathology
See the full eligibility criteria
- Age ≥ 18 years
- signed informed consent
- Patient with unilateral AMD, with at least 1 focus of choroidal neovascularization on OCT, naïve to any antiangiogenic treatment.
- Initial check-up including at least OCT and visual acuity measurement, maximum 1 month old at the time of the 68Ga-NODAGA-RGD PET scan
- affiliation to a social security scheme.
- pregnant or breast-feeding women
- Age ≤ 18 years
- Patients with bilateral AMD
- Patients with AMD with no neovascularization focus as assessed by the standard diagnostic battery
- Patients previously treated with antiangiogenic therapy.
- Patients suffering from any other ophthalmological pathology
- Monophtalmic patients
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.